Search
-
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe
Media
Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. 1,2,3
https://www.gsk.com/en-gb/media/press-releases/gsk-s-paediatric-pneumococcal-candidate-vaccine-synflorix-receives-positive-opinion-in-europe/
First published: 21 January 2009
-
GSK to support manufacture of Novavax’ COVID-19 vaccine
Media
GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine.
https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-manufacture-of-novavax-covid-19-vaccine/
First published: 29 March 2021
-
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Media
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/
First published: 14 April 2020
-
GSK starts Phase III RSV candidate vaccine programme for older adults
Media
Positive Phase I/II results established the robust immunogenicity of the vaccine candidate in the target population
https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-rsv-candidate-vaccine-programme-for-older-adults/
First published: 16 February 2021
-
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
Media
GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-2009-vaccine/
First published: 06 October 2009
-
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
Media
GSK entered into agreement to acquire the remaining 51% equity interest of Neptunus in JV company for a total cash consideration of $39m
https://www.gsk.com/en-gb/media/press-releases/gsk-to-purchase-shenzhen-neptunus-stake-in-previously-formed-joint-venture-for-influenza-vaccines-in-china/
First published: 14 June 2011
-
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Media
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/
First published: 31 July 2020
-
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Media
Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate/
First published: 27 May 2021
-
Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system
Media
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system/
First published: 24 February 2020
-
Sanofi and GSK to supply European Union with up to 300 million doses of COVID-19 vaccine
Media
The agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-supply-european-union-with-up-to-300-million-doses-of-covid-19-vaccine/
First published: 31 July 2020